Edoxaban for Cancer-Associated Venous Thromboembolism

Affiliations

¹ University of Oklahoma Health Sciences Center, Oklahoma City, OK gary-raskob@ouhsc.edu
² Academic Medical Center, Amsterdam, the Netherlands
³ ITREAS Clinical Research, Amsterdam, the Netherlands

Comment

Gary E Raskob et al. N Engl J Med. 2018.

. 2018 Jul 5;379(1):95-96.

doi: 10.1056/NEJMc1806646.

¹ University of Oklahoma Health Sciences Center, Oklahoma City, OK gary-raskob@ouhsc.edu
² Academic Medical Center, Amsterdam, the Netherlands
³ ITREAS Clinical Research, Amsterdam, the Netherlands

No abstract available

Comment on

Edoxaban for Cancer-Associated Venous Thromboembolism.
Calabrò MG, Curigliano G. Calabrò MG, et al. N Engl J Med. 2018 Jul 5;379(1):93. doi: 10.1056/NEJMc1806646. N Engl J Med. 2018. PMID: 29975029 No abstract available.
Edoxaban for Cancer-Associated Venous Thromboembolism.
Hironaka S. Hironaka S. N Engl J Med. 2018 Jul 5;379(1):93-4. doi: 10.1056/NEJMc1806646. N Engl J Med. 2018. PMID: 29975031 No abstract available.
Edoxaban for Cancer-Associated Venous Thromboembolism.
Frere C, Dufilho M. Frere C, et al. N Engl J Med. 2018 Jul 5;379(1):94. doi: 10.1056/NEJMc1806646. N Engl J Med. 2018. PMID: 29975032 No abstract available.
Edoxaban for Cancer-Associated Venous Thromboembolism.
Nasser NJ. Nasser NJ. N Engl J Med. 2018 Jul 5;379(1):94-5. doi: 10.1056/NEJMc1806646. N Engl J Med. 2018. PMID: 29975033 No abstract available.